Figure 5
(A) The effect of Temozolomide (TMZ) on the viability (72 h) of U87 cells pre-treated for 48 h with 11PS04, as determined in the MTT test (n = 3): *p < 0.05, **p < 0.01, ***p < 0.001 relative to the vehicle pre-treated; #p < 0.05, ##p < 0.01, ###p < 0.001 relative to vehicle cells. (B) Sphere frequencies from U87 single-cell suspensions are plotted relative to the number of cells seeded per well, in the presence of 11PS04 (5 μM), TMZ (100 μM) or 11PS04 (5 μM) plus TMZ (100 μM) during the formation of the spheres. Solid lines represent the frequency estimation and the dashed lines the 95% confidence intervals. The right panel shows the frequency of spheres produced by U87 cells pre-treated with 11PS04 (5 μM) or the vehicle alone, and then exposed to 11PS04 (5 μM), TMZ (100 μM) or 11PS04 (5 μM) plus TMZ (100 μM) during the formation of the spheres. The controls are the cells pre-treated and treated during sphere formation with the vehicle alone. (C) The frequency of initiating cancer stem cells was calculated using the ELDA platform.
